A biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.
Desentum has raised €22M across 3 funding rounds from 2 investors, most recently a round in Feb 2024. Based in Espoo, Finland; founded 2011; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-02-20 | Other | €12M | Springvest Oy | View deal → |
| 2022-01-21 | Other | €8.0M | Springvest Oy | View deal → |
| 2018-10-01 | Grant | €1.9M | EU | View deal → |
